[go: up one dir, main page]

US20130095146A1 - Ciclesonide containing aqueous pharmaceutical composition - Google Patents

Ciclesonide containing aqueous pharmaceutical composition Download PDF

Info

Publication number
US20130095146A1
US20130095146A1 US13/688,659 US201213688659A US2013095146A1 US 20130095146 A1 US20130095146 A1 US 20130095146A1 US 201213688659 A US201213688659 A US 201213688659A US 2013095146 A1 US2013095146 A1 US 2013095146A1
Authority
US
United States
Prior art keywords
pharmaceutical composition
aqueous pharmaceutical
composition according
ciclesonide
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/688,659
Inventor
Atsuhiro Nagano
Yoshihisa Nishibe
Kazuya Takanashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nycomed Germany Holding GmbH
Covis Pharma BV
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17856339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20130095146(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US13/688,659 priority Critical patent/US20130095146A1/en
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: NYCOMED GMBH
Publication of US20130095146A1 publication Critical patent/US20130095146A1/en
Assigned to NYCOMED GERMANY HOLDING GMBH reassignment NYCOMED GERMANY HOLDING GMBH MERGER (SEE DOCUMENT FOR DETAILS). Assignors: NYCOMED ASSET MANAGEMENT GMBH
Assigned to NYCOMED ASSET MANAGEMENT GMBH reassignment NYCOMED ASSET MANAGEMENT GMBH MERGER (SEE DOCUMENT FOR DETAILS). Assignors: TAKEDA GMBH
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: NYCOMED GERMANY HOLDING GMBH
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TAKEDA GMBH
Assigned to COVIS PHARMA B.V. reassignment COVIS PHARMA B.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASTRAZENECA AB
Assigned to CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT reassignment CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COVIS PHARMA B.V.
Assigned to CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT reassignment CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COVIS PHARMA B.V.
Assigned to COVIS PHARMA B.V. reassignment COVIS PHARMA B.V. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Assigned to COVIS PHARMA B.V. reassignment COVIS PHARMA B.V. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CAPITAL ONE, NATIONAL ASSOCIATION
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Definitions

  • the present invention relates to a ciclesonide-containing aqueous pharmaceutical composition for use in drug therapy that contains ciclesonide and hydroxypropylmethylcellulose, wherein said ciclesonide is dispersed in an aqueous medium in the form of solid particles. More particularly, the present invention relates to a ciclesonide-containing aqueous pharmaceutical composition having excellent ciclesonide dispersivity during production as compared with conventional aqueous pharmaceutical compositions.
  • Ciclesonide aqueous pharmaceutical compositions containing ciclesonide dispersed in an aqueous medium in a form of solid particles are expected to represent a useful drug form for reasons that include 1) it is not necessary to completely dissolve ciclesonide, 2) it can be directly administered to an affected site by spraying and so forth for treatment of local diseases such as those of the nasal mucosa, eyes and epidermis, and 3) they are easier to swallow than tablets or granule and so forth.
  • ciclesonide When present in an aqueous medium, ciclesonide is resistant to wetting and easily aggregates.
  • wetting agent such as Polysorbate 80 and powerful stirring and so forth during production have been used in the prior art for the purpose of dispersing drug having such properties in an aqueous medium in a stable state.
  • methylcellulose can be used in place of hydroxypropylmethylcellulose for the cellulose-based polymer, while the addition of a nonionic surfactant is also required. It is not easy to deduce the present invention from this patent in which the optimum value of the hydroxypropylmethylcellulose concentration is from 0.01% w/w to 0.5% w/w, and does not require a surfactant.
  • the object of the present invention is to provide a ciclesonide aqueous pharmaceutical composition that avoids variations in ciclesonide concentration during production as well as decreases in the ciclesonide recovery rate.
  • a ciclesonide aqueous pharmaceutical composition can be provided that avoids variations in ciclesonide concentrations during production as well as decreases in the ciclesonide recovery rate, by using a ciclesonide aqueous pharmaceutical composition containing ciclesonide and hydroxypropylmethylcellulose, thereby leading to completion of the present invention.
  • the present invention relates to an aqueous pharmaceutical composition containing ciclesonide and hydroxypropylmethylcellulose, wherein said ciclesonide is dispersed in an aqueous medium in form of solid particles.
  • composition of the present invention contain ciclesonide, while water-soluble, water-low soluble or water-insoluble drugs other than ciclesonide can be added.
  • water-soluble, water-low soluble or water-insoluble drugs other than ciclesonide include vasoconstrictors, bronchodilators, anti-allergic agents and expectorants.
  • ciclesonide particles that can be used in the present invention may be of any size, they are preferably within the range of 10 nm to 100 ⁇ m, and particularly preferably within the range of 10 nm to 10 ⁇ m.
  • a preferable example is a cellulose, and a particularly preferable example is crystalline cellulose.
  • the concentration of water-insoluble substance and/or water-low soluble substance present in form of solid particles in an aqueous medium is preferably 0.3% w/w and above, and particularly preferably 1% w/w to 10% w/w, relative to the total amount of the composition.
  • an aqueous polymer substance can also be added in the present pharmaceutical composition.
  • aqueous polymer substance include propylene glycol alginate, pectin, low methoxyl pectin, gua gum, gum arabic, carrageenan, methylcellulose, carboxymethylcellulose sodium, xanthan gum and hydroxypropylcellulose, while particularly preferable examples include carboxymethylcellulose sodium, polyethylene glycol and hydroxypropylcellulose.
  • crystalline cellulose carmellose sodium is an example of a combination of these water-soluble substances and water-insoluble substances that can be used in the present invention, and it consists of a mixture of carboxymethylcellulose sodium and crystalline cellulose.
  • the concentration of said substance is preferably 1% w/w to 30% w/w relative to the water-insoluble substance and/or water-low soluble substance.
  • the ciclesonide-containing aqueous pharmaceutical composition of the present invention is also required to contain hydroxypropylmethylcellulose. Although this may be of any grade, a specific example is hydroxypropylmethylcellulose 2910.
  • said hydroxypropylmethylcellulose may be present at any concentration, its concentration is preferably from 0.01% w/w to 30% w/w, particularly preferably from 0.01% w/w to 5% w/w, more particularly preferably from 0.01% w/w to 1% w/w, and most preferably from 0.01% w/w to 0.5% w/w, relative to the total amount of composition.
  • a wetting agent although not essential in the present invention, can be added, specific examples of which include Polysorbate 80, glycerin monostearate, polyoxyl stearate, lauromacrogol, sorbitan oleate and sucrose fatty acid esters.
  • a substance for controlling osmotic pressure can be added to control osmotic pressure, specific examples of which include salts such as sodium chloride and water-soluble sugars such as glucose, with glucose being a particularly preferable example.
  • An effective amount of ciclesonide used in the present invention can be determined according to the type and degree of the respective disease, as well as the age and body weight of the patient, and so forth.
  • the concentration of ciclesonide of the present invention is preferably. from 0.01% w/w to 1% w/w, and particularly preferably from 0.05% w/w to 0.5% w/w, relative to the total amount of the composition.
  • Any method for dispersing a water-insoluble substance and/or water-low soluble substance in an aqueous medium may be used for the production of the ciclesonide-containing aqueous pharmaceutical composition in the present invention, a specific example of which is a method that uses a homomixer.
  • antiseptics include benzalkonium chloride
  • pH controlling agents include hydrochloric acid and sodium hydroxide
  • preservatives include ascorbic acid
  • buffers include phosphoric acid and its salt
  • colorants include red dye no. 2
  • smell corrigents include menthol.
  • a ciclesonide aqueous pharmaceutical composition that avoids variations in ciclesonide concentration during production as well as decreases in the recovery rate of ciclesonide more effectively than aqueous pharmaceutical compositions of the prior art. These effects also lead to improved quality as well as decreased production cost due to the higher recovery rate.
  • the present invention has extremely high significance in terms of both quality and economy for the production of ciclesonide aqueous pharmaceutical compositions.
  • Ciclesonide used in the present invention was manufactured by Byk Gulden Co., the crystalline cellulose carmellose sodium by Asahi Chemical Industry Co., Ltd. (AvicelTM RC-A591NF), hydroxypropylmethylcellulose 2910 by Shin-Etsu Chemical Co., Ltd. (TC-5RWTM or Metrose 60SH-4000TM), Polysorbate 80 by Nippon Surfactant Co., Ltd., and the sorbitan trioleate by Nikko Chemical Co., Ltd. ROBOMICSTM manufactured by Tokushu Kika Kogyo Co., Ltd. was used for the homomixer.
  • Ciclesonide aqueous pharmaceutical compositions containing the components indicated below were prepared on a 300 ml scale by processing with a homomixer.
  • Homomixer processing was performed at 6000 rpm for 30 minutes.
  • Ciclesonide 0.1% w/w
  • Crystalline cellulose carmellose sodium 1.7% w/w
  • Hydroxypropylmethylcellulose 2910 (TC-5RWTM): 0.01% w/w
  • Ciclesonide 0.1% w/w
  • Crystalline cellulose carmellose sodium 1.7% w/w
  • Hydroxypropylmethylcellulose 2910 (TC-5RWTM): 0.1% w/w
  • Ciclesonide 0.1% w/w
  • Crystalline cellulose carmellose sodium 1.7% w/w
  • Hydroxypropylmethylcellulose 2910 (TC-5RWTM): 1% w/w
  • Ciclesonide 0.1% w/w
  • Crystalline cellulose carmellose sodium 1.7% w/w
  • Hydroxypropylmethylcellulose 2910 (Metrose 60SH-4000TM): 0.01% w/w
  • Ciclesonide 0.1% w/w
  • Crystalline cellulose carmellose sodium 1.7% w/w
  • Hydroxypropylmethylcellulose 2910 (Metrose 60SH-4000TM): 0.1% w/w
  • the ciclesonide aqueous pharmaceutical compositions were collected from the upper and lower portions of the emulsification tank, followed by quantification of the ciclesonide concentrations by HPLC.
  • the value for the upper portion of the emulsification tank was calculated by taking the ciclesonide concentration in the lower portion of the emulsification tank to be 100%.
  • the ciclesonide concentrations of the ciclesonide aqueous pharmaceutical compositions recovered from the emulsification tank were quantified by HPLC, and the ciclesonide recovery rates were determined based on the theoretical value of the ciclesonide concentration as calculated from the charged amount.
  • Ciclesonide aqueous pharmaceutical compositions containing the components indicated below were prepared on a 300 ml scale by processing with a homomixer. Homomixer processing was performed at 6000 rpm for 30 minutes.
  • Ciclesonide 0.1% w/w
  • Crystalline cellulose carmellose sodium 1.7% w/w
  • Polysorbate 80 0.1% w/w
  • Ciclesonide 0.1% w/w
  • Crystalline cellulose carmellose sodium 1.7% w/w
  • Sorbitan trioleate 0.1% w/w
  • the ciclesonide aqueous pharmaceutical compositions were collected from the upper and lower portions of the emulsification tank, followed by quantification of the ciclesonide concentrations by HPLC.
  • the value for the upper portion of the emulsification tank was calculated by taking the ciclesonide concentration in the lower portion of the emulsification tank to be 100%.
  • the ciclesonide concentrations of the ciclesonide aqueous pharmaceutical compositions recovered from the emulsification tank were quantified by HPLC, and the ciclesonide recovery rates were determined based on the theoretical value of the ciclesonide concentration as calculated from the charged amount.
  • compositions 2, 3 and 5 which contained 0.1 to 1% w/w of hydroxypropylmethylcellulose 2910, the ciclesonide concentrations in the emulsification tank immediately after homomixer processing were uniform, and the recovery rates were almost 100%.
  • compositions 1 and 4 which contained 0.01% w/w of hydroxypropylmethylcellulose 2910, although the ciclesonide concentrations in the emulsification tank immediately after homomixer processing were somewhat non-uniform, the recovery rates were almost 100%.
  • composition 6 which contained 0.1% w/w of Polysorbate 80, the ciclesonide concentration in the upper portion of the emulsification tank immediately after homomixer processing was more than 30% higher than in the lower portion.
  • composition 7 which contained 0.1% w/w of sorbitan trioleate
  • the ciclesonide concentration in the upper portion of the emulsification tank immediately after homomixer processing was more than 40% higher than in the lower portion, and the recovery rate decreased by more than half.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

An aqueous pharmaceutical composition which comprises ciclesonide, crystalline cellulose carmellose sodium and hydroxypropylmethylcellulose is provided.

Description

    FIELD OF INVENTION
  • The present invention relates to a ciclesonide-containing aqueous pharmaceutical composition for use in drug therapy that contains ciclesonide and hydroxypropylmethylcellulose, wherein said ciclesonide is dispersed in an aqueous medium in the form of solid particles. More particularly, the present invention relates to a ciclesonide-containing aqueous pharmaceutical composition having excellent ciclesonide dispersivity during production as compared with conventional aqueous pharmaceutical compositions.
    • BACKGROUND ART
  • Ciclesonide aqueous pharmaceutical compositions containing ciclesonide dispersed in an aqueous medium in a form of solid particles are expected to represent a useful drug form for reasons that include 1) it is not necessary to completely dissolve ciclesonide, 2) it can be directly administered to an affected site by spraying and so forth for treatment of local diseases such as those of the nasal mucosa, eyes and epidermis, and 3) they are easier to swallow than tablets or granule and so forth.
  • When present in an aqueous medium, ciclesonide is resistant to wetting and easily aggregates. The addition of wetting agent such as Polysorbate 80 and powerful stirring and so forth during production have been used in the prior art for the purpose of dispersing drug having such properties in an aqueous medium in a stable state.
  • Improvement of drug dispersivity of aqueous pharmaceutical compositions containing a drug dispersed in an aqueous medium in form of solid particles by addition of cellulose-based polymer is disclosed in Morishima et al. patent specification of WO99-37286. However, this patent relates to the redispersion of a drug that has settled during storage, and is fundamentally different from the present invention which relates to overcoming drawbacks of the migration of ciclesonide towards bubbles formed by powerful stirring during the production, and the adsorption of ciclesonide to the walls of the production apparatus. Moreover, the concentration of the cellulose-based polymer in the patent specification of Morishima et al. is 0.0001 to 0.003%, and methylcellulose can be used in place of hydroxypropylmethylcellulose for the cellulose-based polymer, while the addition of a nonionic surfactant is also required. It is not easy to deduce the present invention from this patent in which the optimum value of the hydroxypropylmethylcellulose concentration is from 0.01% w/w to 0.5% w/w, and does not require a surfactant.
    • DISCLOSURE OF THE INVENTION
  • During the course of production of ciclesonide aqueous pharmaceutical compositions, high shearing force is required to disperse ciclesonide and it is necessary to powerfully stir ciclesonide-containing aqueous pharmaceutical composition. Ciclesonide migrates to the bubbles formed at this time. Since this results in an increased concentration of ciclesonide in the upper portion of the ciclesonide aqueous pharmaceutical composition being higher than that in the lower portion, variation occurs in the ciclesonide concentration of ciclesonide aqueous pharmaceutical compositions produced. Moreover, the recovery rate decreases due to adsorption of ciclesonide to the walls and so forth of the production apparatus.
  • These variations in ciclesonide concentration and adsorption of ciclesonide to the production apparatus were hardly improved at all by the addition of wetting agents such as Polysorbate 80 that have been used in the prior art. Conversely, the amount of formed bubbles increases resulting in promotion of further variation in ciclesonide concentration.
  • Therefore, there is a considerable need for the development of a ciclesonide aqueous pharmaceutical composition that is able to avoid variations in ciclesonide concentrations during production as well as the decrease in ciclesonide recovery rate.
  • Namely, the object of the present invention is to provide a ciclesonide aqueous pharmaceutical composition that avoids variations in ciclesonide concentration during production as well as decreases in the ciclesonide recovery rate.
  • As a result of earnest studies to solve the above problems, the inventors of the present invention found that a ciclesonide aqueous pharmaceutical composition can be provided that avoids variations in ciclesonide concentrations during production as well as decreases in the ciclesonide recovery rate, by using a ciclesonide aqueous pharmaceutical composition containing ciclesonide and hydroxypropylmethylcellulose, thereby leading to completion of the present invention.
  • Namely, the present invention relates to an aqueous pharmaceutical composition containing ciclesonide and hydroxypropylmethylcellulose, wherein said ciclesonide is dispersed in an aqueous medium in form of solid particles.
    • EMBODIMENT FOR CARRYING OUT THE INVENTION
  • It is essential that composition of the present invention contain ciclesonide, while water-soluble, water-low soluble or water-insoluble drugs other than ciclesonide can be added. Specific examples of these include vasoconstrictors, bronchodilators, anti-allergic agents and expectorants.
  • Although the ciclesonide particles that can be used in the present invention may be of any size, they are preferably within the range of 10 nm to 100 μm, and particularly preferably within the range of 10 nm to 10 μm.
  • Although any substances may be used for the water-insoluble or water-low soluble substance that can be used in the present invention, a preferable example is a cellulose, and a particularly preferable example is crystalline cellulose.
  • In the present invention, the concentration of water-insoluble substance and/or water-low soluble substance present in form of solid particles in an aqueous medium is preferably 0.3% w/w and above, and particularly preferably 1% w/w to 10% w/w, relative to the total amount of the composition.
  • In addition, an aqueous polymer substance can also be added in the present pharmaceutical composition. Specific examples of such include propylene glycol alginate, pectin, low methoxyl pectin, gua gum, gum arabic, carrageenan, methylcellulose, carboxymethylcellulose sodium, xanthan gum and hydroxypropylcellulose, while particularly preferable examples include carboxymethylcellulose sodium, polyethylene glycol and hydroxypropylcellulose. In addition, crystalline cellulose carmellose sodium, is an example of a combination of these water-soluble substances and water-insoluble substances that can be used in the present invention, and it consists of a mixture of carboxymethylcellulose sodium and crystalline cellulose. Furthermore, in the case of adding these water-soluble polymer substances, the concentration of said substance is preferably 1% w/w to 30% w/w relative to the water-insoluble substance and/or water-low soluble substance.
  • The ciclesonide-containing aqueous pharmaceutical composition of the present invention is also required to contain hydroxypropylmethylcellulose. Although this may be of any grade, a specific example is hydroxypropylmethylcellulose 2910.
  • Although said hydroxypropylmethylcellulose may be present at any concentration, its concentration is preferably from 0.01% w/w to 30% w/w, particularly preferably from 0.01% w/w to 5% w/w, more particularly preferably from 0.01% w/w to 1% w/w, and most preferably from 0.01% w/w to 0.5% w/w, relative to the total amount of composition.
  • A wetting agent, although not essential in the present invention, can be added, specific examples of which include Polysorbate 80, glycerin monostearate, polyoxyl stearate, lauromacrogol, sorbitan oleate and sucrose fatty acid esters.
  • In the present invention, a substance for controlling osmotic pressure (osmotic pressure-controlling agent) can be added to control osmotic pressure, specific examples of which include salts such as sodium chloride and water-soluble sugars such as glucose, with glucose being a particularly preferable example.
  • An effective amount of ciclesonide used in the present invention can be determined according to the type and degree of the respective disease, as well as the age and body weight of the patient, and so forth.
  • The concentration of ciclesonide of the present invention is preferably. from 0.01% w/w to 1% w/w, and particularly preferably from 0.05% w/w to 0.5% w/w, relative to the total amount of the composition.
  • Any method for dispersing a water-insoluble substance and/or water-low soluble substance in an aqueous medium may be used for the production of the ciclesonide-containing aqueous pharmaceutical composition in the present invention, a specific example of which is a method that uses a homomixer.
  • Known antiseptics, pH controlling agents, preservatives, buffers, colorants, smell corrigents and so forth may be added as necessary to the composition of the present invention to improve its physical properties, appearance or odor and so forth of the formulation. Examples of antiseptics include benzalkonium chloride, examples of pH controlling agents include hydrochloric acid and sodium hydroxide, examples of preservatives include ascorbic acid, examples of buffers include phosphoric acid and its salt, examples of colorants include red dye no. 2, and examples of smell corrigents include menthol.
  • According to the present invention as described above, a ciclesonide aqueous pharmaceutical composition is provided that avoids variations in ciclesonide concentration during production as well as decreases in the recovery rate of ciclesonide more effectively than aqueous pharmaceutical compositions of the prior art. These effects also lead to improved quality as well as decreased production cost due to the higher recovery rate.
  • Thus, the present invention has extremely high significance in terms of both quality and economy for the production of ciclesonide aqueous pharmaceutical compositions.
    • EXAMPLES
  • The following provides an explanation of the present invention through its Examples.
  • Ciclesonide used in the present invention was manufactured by Byk Gulden Co., the crystalline cellulose carmellose sodium by Asahi Chemical Industry Co., Ltd. (Avicel™ RC-A591NF), hydroxypropylmethylcellulose 2910 by Shin-Etsu Chemical Co., Ltd. (TC-5RW™ or Metrose 60SH-4000™), Polysorbate 80 by Nippon Surfactant Co., Ltd., and the sorbitan trioleate by Nikko Chemical Co., Ltd. ROBOMICS™ manufactured by Tokushu Kika Kogyo Co., Ltd. was used for the homomixer.
    • Example 1
  • Ciclesonide aqueous pharmaceutical compositions containing the components indicated below were prepared on a 300 ml scale by processing with a homomixer.
  • Homomixer processing was performed at 6000 rpm for 30 minutes.
  • Composition (1)
  • Ciclesonide: 0.1% w/w
  • Crystalline cellulose carmellose sodium: 1.7% w/w
  • Hydroxypropylmethylcellulose 2910 (TC-5RW™): 0.01% w/w
  • Composition (2)
  • Ciclesonide: 0.1% w/w
  • Crystalline cellulose carmellose sodium: 1.7% w/w
  • Hydroxypropylmethylcellulose 2910 (TC-5RW™): 0.1% w/w
  • Composition (3)
  • Ciclesonide: 0.1% w/w
  • Crystalline cellulose carmellose sodium: 1.7% w/w
  • Hydroxypropylmethylcellulose 2910 (TC-5RW™): 1% w/w
  • Composition (4)
  • Ciclesonide: 0.1% w/w
  • Crystalline cellulose carmellose sodium: 1.7% w/w
  • Hydroxypropylmethylcellulose 2910 (Metrose 60SH-4000™): 0.01% w/w
  • Composition (5)
  • Ciclesonide: 0.1% w/w
  • Crystalline cellulose carmellose sodium: 1.7% w/w
  • Hydroxypropylmethylcellulose 2910 (Metrose 60SH-4000™): 0.1% w/w
  • Immediately after processing compositions 1 to 5 with the homomixer, the ciclesonide aqueous pharmaceutical compositions were collected from the upper and lower portions of the emulsification tank, followed by quantification of the ciclesonide concentrations by HPLC. The value for the upper portion of the emulsification tank was calculated by taking the ciclesonide concentration in the lower portion of the emulsification tank to be 100%.
  • Subsequently, the ciclesonide concentrations of the ciclesonide aqueous pharmaceutical compositions recovered from the emulsification tank were quantified by HPLC, and the ciclesonide recovery rates were determined based on the theoretical value of the ciclesonide concentration as calculated from the charged amount.
  • Those values are shown in Table 1.
    • Comparative Example 1
  • Ciclesonide aqueous pharmaceutical compositions containing the components indicated below were prepared on a 300 ml scale by processing with a homomixer. Homomixer processing was performed at 6000 rpm for 30 minutes.
  • Composition (6)
  • Ciclesonide: 0.1% w/w
  • Crystalline cellulose carmellose sodium: 1.7% w/w
  • Polysorbate 80: 0.1% w/w
  • Composition (7)
  • Ciclesonide: 0.1% w/w
  • Crystalline cellulose carmellose sodium: 1.7% w/w
  • Sorbitan trioleate: 0.1% w/w
  • Immediately after processing compositions 6 and 7 with the homomixer, the ciclesonide aqueous pharmaceutical compositions were collected from the upper and lower portions of the emulsification tank, followed by quantification of the ciclesonide concentrations by HPLC. The value for the upper portion of the emulsification tank was calculated by taking the ciclesonide concentration in the lower portion of the emulsification tank to be 100%.
  • Subsequently, the ciclesonide concentrations of the ciclesonide aqueous pharmaceutical compositions recovered from the emulsification tank were quantified by HPLC, and the ciclesonide recovery rates were determined based on the theoretical value of the ciclesonide concentration as calculated from the charged amount.
  • Those values are shown in Table 1.
  • TABLE 1
    Ciclesonide concentration
    immediately after processing
    (%)
    Upper portion Lower portion
    of emulsi- of emulsi- Recovery
    Preparation fication tank fication tank rate (%)
    Embodiment 1 Composition 1 138.1 100.0 104.2
    Composition 2 100.3 100.0 100.7
    Composition 3 99.6 100.0 101.5
    Composition 4 147.9 100.0 98.4
    Composition 5 100.4 100.0 100.8
    Comparative Composition 6 131.1 100.0 78.2
    Example 1 Composition 7 438.7 100.0 43.0
  • In the case of compositions 2, 3 and 5, which contained 0.1 to 1% w/w of hydroxypropylmethylcellulose 2910, the ciclesonide concentrations in the emulsification tank immediately after homomixer processing were uniform, and the recovery rates were almost 100%. In addition, in the case of compositions 1 and 4, which contained 0.01% w/w of hydroxypropylmethylcellulose 2910, although the ciclesonide concentrations in the emulsification tank immediately after homomixer processing were somewhat non-uniform, the recovery rates were almost 100%. In contrast, in the case of composition 6, which contained 0.1% w/w of Polysorbate 80, the ciclesonide concentration in the upper portion of the emulsification tank immediately after homomixer processing was more than 30% higher than in the lower portion. In addition, the recovery rate decreased by about 20%. In the case of composition 7, which contained 0.1% w/w of sorbitan trioleate, the ciclesonide concentration in the upper portion of the emulsification tank immediately after homomixer processing was more than 40% higher than in the lower portion, and the recovery rate decreased by more than half.
  • Based on these results, it was determined that the use of a composition containing hydroxypropylmethylcellulose made it possible to avoid variation in the concentration of ciclesonide during production as well as avoid a decrease in the recovery rate of ciclesonide.

Claims (32)

1-14. (canceled)
15. An aqueous pharmaceutical composition which comprises ciclesonide, crystalline cellulose carmellose sodium and hydroxypropylmethylcellulose, wherein said crystalline cellulose carmellose sodium concentration is 1.7% w/w, and wherein said hydroxypropylmethylcellulose concentration is from 0.1% w/w to 0.5% w/w, relative to the total amount of the composition.
16. An aqueous pharmaceutical composition according to claim 15, which further comprises one or more types of a water-insoluble substance and/or water-low soluble substance which is one or more types of cellulose.
17. An aqueous pharmaceutical composition according to claim 16, which further comprises a water-soluble polymer substance.
18. An aqueous pharmaceutical composition according to claim 17, wherein said water-soluble polymer substance is one or more types selected from the group consisting of polyethylene glycol, propylene glycol alginate, pectin, methoxyl pectin, guar gum, gum arabic, carrageenan, methylcellulose, xanthan gum and hydroxypropylcellulose.
19. An aqueous pharmaceutical composition according to claim 17, wherein said water-soluble polymer substance is polyethylene glycol.
20. An aqueous pharmaceutical composition according to claim 17, wherein said water-soluble polymer substance is hydroxypropylcellulose.
21. An aqueous pharmaceutical composition according to claim 15, which further comprises a water-soluble polymer substance.
22. An aqueous pharmaceutical composition according to claim 21, wherein said water-soluble polymer substance is one or more types selected from the group consisting of polyethylene glycol, propylene glycol alginate, pectin, methoxyl pectin, guar gum, gum arabic, carrageenan, methylcellulose, xanthan gum and hydroxypropylcellulose.
23. An aqueous pharmaceutical composition according to claim 21, wherein said water-soluble polymer substance is polyethylene glycol.
24. An aqueous pharmaceutical composition according to claim 21, wherein said water-soluble polymer substance is hydroxypropylcellulose.
25. An aqueous pharmaceutical composition according to claim 15, wherein the ciclesonide particles have a size of between about 10 nm and about 100 μm.
26. An aqueous pharmaceutical composition according to claim 15, wherein the ciclesonide particles have a size of between about 10 nm and about 10 μm.
27. An aqueous pharmaceutical composition according to claim 15, further comprising at least one wetting agent.
28. An aqueous pharmaceutical composition according to claim 27, wherein at least one wetting agent present is selected from the group consisting of Polysorbate 80, glycerin monostearate, polyoxyl stearate, lauromacrogol, sorbitan oleate and sucrose fatty acid esters.
29. An aqueous pharmaceutical composition according to claim 15, further comprising at least one osmotic-pressure controlling agent.
30. An aqueous pharmaceutical composition according to claim 29, wherein at least one osmotic-pressure controlling agent present is a salt.
31. An aqueous pharmaceutical composition according to claim 30, wherein the salt is sodium chloride.
32. An aqueous pharmaceutical composition according to claim 29, wherein at least one osmotic-pressure controlling agent present is a water-soluble sugar.
33. An aqueous pharmaceutical composition according to claim 32, wherein the water-soluble sugar is glucose.
34. An aqueous pharmaceutical composition according to claim 15, wherein the ciclesonide is present in a concentration of between about 0.01% w/w and about 1% w/w, relative to the total amount of the composition.
35. An aqueous pharmaceutical composition according to claim 15, wherein the ciclesonide is present in a concentration of between about 0.05% w/w and about 0.5% w/w, relative to the total amount of the composition.
36. An aqueous pharmaceutical composition according to claim 15, further comprising at least one antiseptic.
37. An aqueous pharmaceutical composition according to claim 36, wherein at least one antiseptic present is benzalkonium chloride.
38. An aqueous pharmaceutical composition according to claim 15, further comprising at least one pH controlling agent.
39. An aqueous pharmaceutical composition according to claim 38, wherein at least one pH controlling agent present is selected from the group consisting of hydrochloric acid and sodium hydroxide.
40. An aqueous pharmaceutical composition according to claim 38, wherein the at least one pH controlling agent is hydrochloric acid.
41. An aqueous pharmaceutical composition according to claim 15, further comprising at least one preservative.
42. An aqueous pharmaceutical composition according to claim 41, wherein at least one preservative present is ascorbic acid.
43. An aqueous pharmaceutical composition according to claim 15, further comprising at least one buffer.
44. An aqueous pharmaceutical composition according to claim 43, wherein at least one buffer present is selected from the group consisting of phosphoric acid and salts thereof.
45. An aqueous pharmaceutical composition according to claim 15, further comprising
(a) at least one pH controlling agent, and
(b) at least one antiseptic or at least one preservative.
US13/688,659 1999-10-20 2012-11-29 Ciclesonide containing aqueous pharmaceutical composition Abandoned US20130095146A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/688,659 US20130095146A1 (en) 1999-10-20 2012-11-29 Ciclesonide containing aqueous pharmaceutical composition

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP11-298186 1999-10-20
JP29818699 1999-10-20
PCT/JP2000/007351 WO2001028563A1 (en) 1999-10-20 2000-10-20 Ciclesonide-containing aqueous pharmaceutical composition
US11063202A 2002-07-15 2002-07-15
US13/688,659 US20130095146A1 (en) 1999-10-20 2012-11-29 Ciclesonide containing aqueous pharmaceutical composition

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2000/007351 Continuation WO2001028563A1 (en) 1999-10-20 2000-10-20 Ciclesonide-containing aqueous pharmaceutical composition
US11063202A Continuation 1999-10-20 2002-07-15

Publications (1)

Publication Number Publication Date
US20130095146A1 true US20130095146A1 (en) 2013-04-18

Family

ID=17856339

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/110,632 Expired - Fee Related US8383611B1 (en) 1999-10-20 2000-10-20 Ciclesonide containing aqueous pharmaceutical composition
US13/688,659 Abandoned US20130095146A1 (en) 1999-10-20 2012-11-29 Ciclesonide containing aqueous pharmaceutical composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/110,632 Expired - Fee Related US8383611B1 (en) 1999-10-20 2000-10-20 Ciclesonide containing aqueous pharmaceutical composition

Country Status (35)

Country Link
US (2) US8383611B1 (en)
EP (1) EP1227817B1 (en)
JP (1) JP4856338B2 (en)
KR (1) KR100705372B1 (en)
CN (1) CN1198623C (en)
AR (1) AR026073A1 (en)
AT (1) ATE270107T1 (en)
AU (1) AU776587B2 (en)
BG (1) BG65799B1 (en)
BR (1) BRPI0014880B8 (en)
CA (1) CA2388325C (en)
CO (1) CO5251406A1 (en)
CZ (1) CZ297780B6 (en)
DE (1) DE60011924T2 (en)
DK (1) DK1227817T3 (en)
EA (1) EA005201B1 (en)
ES (1) ES2223595T3 (en)
HR (1) HRP20020345B1 (en)
HU (1) HU228894B1 (en)
IL (2) IL148725A0 (en)
ME (1) ME00568B (en)
MX (1) MXPA02003975A (en)
MY (1) MY121175A (en)
NO (1) NO327379B1 (en)
NZ (1) NZ518299A (en)
PE (1) PE20010713A1 (en)
PL (1) PL197537B1 (en)
PT (1) PT1227817E (en)
RS (1) RS50345B (en)
SI (1) SI1227817T1 (en)
SK (1) SK286194B6 (en)
TR (1) TR200200831T2 (en)
TW (1) TWI269655B (en)
WO (1) WO2001028563A1 (en)
ZA (1) ZA200203078B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11992556B2 (en) 2011-08-18 2024-05-28 Covis Pharma Gmbh Pharmaceutical aerosol product for administration by oral or nasal inhalation

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR026073A1 (en) * 1999-10-20 2002-12-26 Nycomed Gmbh PHARMACEUTICAL COMPOSITION AQUATIC CONTAINING CICLESONIDE
EP1519734A4 (en) 2002-07-02 2011-02-23 Nycomed Gmbh Ciclesonide-containing sterile aqueous suspension
JP4746318B2 (en) 2002-08-30 2011-08-10 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング A pharmaceutical composition for the treatment of allergic rhinitis comprising a combination of ciclesonide and an antihistamine
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
DK1670482T4 (en) 2003-09-16 2022-08-22 Covis Pharma B V USE OF CICLESONIDE IN THE TREATMENT OF RESPIRATORY DISEASES
PE20050941A1 (en) * 2003-12-16 2005-11-08 Nycomed Gmbh AQUEOUS CYCLESOUND SUSPENSIONS FOR MISTING
CA2588433A1 (en) * 2004-11-17 2006-05-26 Michael R. Robinson Steroid formulation and methods of treatment using same
JP5661985B2 (en) * 2006-12-27 2015-01-28 帝人ファーマ株式会社 Aseptic aqueous suspension formulation
WO2009114521A1 (en) 2008-03-11 2009-09-17 Alcon Research, Ltd. Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383611B1 (en) * 1999-10-20 2013-02-26 Nycomed Gmbh Ciclesonide containing aqueous pharmaceutical composition

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
CH657779A5 (en) 1982-10-05 1986-09-30 Sandoz Ag GALENIC COMPOSITIONS CONTAINING CALCITONIN.
AU572815B2 (en) 1982-12-29 1988-05-19 Armour Pharmaceutical Company Pharmaceutical calcitonin compositions for intranasal application
JPS59163313A (en) 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
JPH0830004B2 (en) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド Bioadhesive composition and method of treatment therewith
GB8515132D0 (en) 1985-06-14 1985-07-17 British Nuclear Fuels Plc Measuring photosynthetic activities of plants
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
MY102411A (en) 1986-12-23 1992-06-17 Ciba Geigy Ag Nasal solutions
JPH0744940B2 (en) 1986-12-24 1995-05-17 ライオン株式会社 Base material for oral application
US4802967A (en) 1987-04-08 1989-02-07 Andus Corporation Surface treatment of polymers
JPS63303931A (en) 1987-06-05 1988-12-12 Sumitomo Pharmaceut Co Ltd Growth hormone-releasing active substance preparation for nasal administration
US4788220A (en) 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5776493A (en) 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
DK0431719T3 (en) 1989-10-31 1995-02-27 Columbia Lab Inc Vaginal tissue wetting agent
US5147654A (en) 1990-07-23 1992-09-15 Alza Corporation Oral osmotic device for delivering nicotine
JPH078806B2 (en) 1990-08-16 1995-02-01 旭化成工業株式会社 Nasal emulsion containing calcitonin
GB9102579D0 (en) 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
GB9103824D0 (en) 1991-02-23 1991-04-10 Fisons Ag Formulation
DE69233116T2 (en) 1991-04-03 2004-08-26 Keimowitz, Rudolph M.D., Wayzata SUPPRESSION OF THE THROMBOX MIRROR BY PERCUTANEOUS ADMINISTRATION OF ASPIRIN
IT1250691B (en) * 1991-07-22 1995-04-21 Giancarlo Santus THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION INCLUDING KETOROLAC.
US5200195A (en) 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
JP2860729B2 (en) 1992-03-10 1999-02-24 エスエス製薬株式会社 Planoprofen suspension syrup
CA2101126A1 (en) 1992-08-03 1994-02-04 Yasushi Morita Preparation for local treatment
JP3047948B2 (en) 1992-12-07 2000-06-05 株式会社ツムラ Composition for nasal administration of peptides
US5340572A (en) 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5409703A (en) 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
JP2787131B2 (en) 1993-07-30 1998-08-13 千寿製薬株式会社 Aqueous suspension
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
JP3781792B2 (en) 1993-12-27 2006-05-31 千寿製薬株式会社 Ophthalmic suspension containing difluprednate
JPH07188059A (en) 1993-12-28 1995-07-25 Rohto Pharmaceut Co Ltd Therapeutic agent for periodontosis
RU2102979C1 (en) 1994-07-18 1998-01-27 Панкрушева Татьяна Александровна Agent for treatment of suppurative-inflammatory skin and mucous membrane process
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
AU6392496A (en) 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
JP3098401B2 (en) 1995-07-12 2000-10-16 株式会社エルティーティー研究所 Formulation for nasal administration
JP2791317B2 (en) 1995-12-26 1998-08-27 株式会社三和化学研究所 Multilayer film preparation
ES2205177T5 (en) 1996-02-27 2007-08-01 Teijin Limited POWDER COMPOSITION FOR NASAL ADMINISTRATION.
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
IT1286496B1 (en) 1996-11-20 1998-07-15 Leetrim Ltd Dublin ORAL PHARMACEUTICAL COMPOSITION WITH ANTIPYRETIC, ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY
SE9604486D0 (en) 1996-12-05 1996-12-05 Astra Ab Novel formulation
FR2756739B1 (en) 1996-12-05 2000-04-28 Astra Ab NEW BUDESONIDE FORMULATION
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
JPH1121229A (en) 1997-06-30 1999-01-26 Kyoto Yakuhin Kogyo Kk Antifungal external preparation and its production
JPH11130658A (en) 1997-10-30 1999-05-18 Teijin Ltd Aqueous suspension pharmaceutical composition
JP3386348B2 (en) 1997-10-30 2003-03-17 帝人株式会社 Aqueous suspension formulation for intranasal administration
JP3386349B2 (en) 1997-10-30 2003-03-17 帝人株式会社 Aqueous suspension pharmaceutical composition
SE9704186D0 (en) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
KR100683510B1 (en) 1998-01-22 2007-02-16 산텐 세이야꾸 가부시키가이샤 Fluorometholone suspension eye drops
SE514128C2 (en) * 1998-03-17 2001-01-08 Pharmalink Ab Use of a glucocorticoid for the manufacture of a medicament for the treatment of glomerulonephritis
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US6124268A (en) * 1999-02-17 2000-09-26 Natreon Inc. Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof
RU11829U1 (en) 1999-05-05 1999-11-16 Специальное конструкторское бюро транспортного машиностроения (ОАО Спецмаш) WORKING PLACE FOR DRILLING RIGS
AR026072A1 (en) 1999-10-20 2002-12-26 Nycomed Gmbh PHARMACEUTICAL COMPOSITION CONTAINING CICLESONIDE FOR MUCOSA APPLICATION
WO2001028517A1 (en) 1999-10-20 2001-04-26 Teijin Limited Aqueous medicinal compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383611B1 (en) * 1999-10-20 2013-02-26 Nycomed Gmbh Ciclesonide containing aqueous pharmaceutical composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Isogai et al. Cellulose, 1998, Volume 5, pages 309-319. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11992556B2 (en) 2011-08-18 2024-05-28 Covis Pharma Gmbh Pharmaceutical aerosol product for administration by oral or nasal inhalation
US12370141B2 (en) 2011-08-18 2025-07-29 Covis Pharma Gmbh Pharmaceutical aerosol product for administration by oral or nasal inhalation

Also Published As

Publication number Publication date
TWI269655B (en) 2007-01-01
YU28102A (en) 2004-12-31
RS50345B (en) 2009-11-10
EP1227817B1 (en) 2004-06-30
SI1227817T1 (en) 2004-12-31
EA200200383A1 (en) 2002-10-31
HRP20020345A2 (en) 2005-10-31
HUP0203756A2 (en) 2003-05-28
IL148725A (en) 2006-12-31
KR100705372B1 (en) 2007-04-11
NZ518299A (en) 2004-03-26
PE20010713A1 (en) 2001-07-13
CN1198623C (en) 2005-04-27
SK286194B6 (en) 2008-05-06
CZ297780B6 (en) 2007-03-28
NO20021866D0 (en) 2002-04-19
ES2223595T3 (en) 2005-03-01
SK6932002A3 (en) 2002-09-10
PL356190A1 (en) 2004-06-14
IL148725A0 (en) 2002-09-12
BRPI0014880B1 (en) 2015-08-11
ATE270107T1 (en) 2004-07-15
DE60011924T2 (en) 2005-07-07
AU7953200A (en) 2001-04-30
CZ20021284A3 (en) 2002-07-17
PL197537B1 (en) 2008-04-30
EA005201B1 (en) 2004-12-30
CA2388325C (en) 2007-09-18
ZA200203078B (en) 2003-01-29
KR20020060205A (en) 2002-07-16
PT1227817E (en) 2004-11-30
JP2003512330A (en) 2003-04-02
CN1379673A (en) 2002-11-13
ME00568A (en) 2011-12-20
HU228894B1 (en) 2013-06-28
CO5251406A1 (en) 2003-02-28
BR0014880A (en) 2002-06-11
BG106517A (en) 2002-12-29
DK1227817T3 (en) 2004-11-15
WO2001028563A1 (en) 2001-04-26
BG65799B1 (en) 2009-12-31
HRP20020345B1 (en) 2006-12-31
MY121175A (en) 2005-12-30
NO20021866L (en) 2002-04-19
ME00568B (en) 2011-12-20
CA2388325A1 (en) 2001-04-26
AU776587B2 (en) 2004-09-16
MXPA02003975A (en) 2003-09-25
DE60011924D1 (en) 2004-08-05
HUP0203756A3 (en) 2004-06-28
JP4856338B2 (en) 2012-01-18
AR026073A1 (en) 2002-12-26
EP1227817A1 (en) 2002-08-07
TR200200831T2 (en) 2002-07-22
NO327379B1 (en) 2009-06-22
BRPI0014880B8 (en) 2021-05-25
HK1051003A1 (en) 2003-07-18
US8383611B1 (en) 2013-02-26

Similar Documents

Publication Publication Date Title
US20130095146A1 (en) Ciclesonide containing aqueous pharmaceutical composition
EP2089060B1 (en) Liquid preparation comprising a complex of pimobendan and cyclodextrin
AU757786B2 (en) Formulations of fexofenadine
EP2465497A1 (en) Pharmaceutical suspension composition
CN114007588A (en) Stable and preserved pharmaceutical composition of bilastine
EP1142565A1 (en) Aqueous medicinal compositions
EP0248740A2 (en) A composition of aluminium hydroxide gel
EP3160441B1 (en) Thioureylene liquid compositions
HK1037544A (en) Aqueous medicinal compositions
JPWO2001028517A1 (en) Aqueous Pharmaceutical Composition
HK1051003B (en) Ciclesonide-containing aqueous pharmaceutical composition

Legal Events

Date Code Title Description
AS Assignment

Owner name: TAKEDA GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:NYCOMED GMBH;REEL/FRAME:030091/0737

Effective date: 20121114

AS Assignment

Owner name: NYCOMED ASSET MANAGEMENT GMBH, GERMANY

Free format text: MERGER;ASSIGNOR:TAKEDA GMBH;REEL/FRAME:036193/0224

Effective date: 20121025

Owner name: NYCOMED GERMANY HOLDING GMBH, GERMANY

Free format text: MERGER;ASSIGNOR:NYCOMED ASSET MANAGEMENT GMBH;REEL/FRAME:036201/0478

Effective date: 20141020

AS Assignment

Owner name: TAKEDA GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:NYCOMED GERMANY HOLDING GMBH;REEL/FRAME:036205/0179

Effective date: 20141020

AS Assignment

Owner name: ASTRAZENECA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TAKEDA GMBH;REEL/FRAME:041328/0362

Effective date: 20160429

AS Assignment

Owner name: COVIS PHARMA B.V., NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTRAZENECA AB;REEL/FRAME:047761/0435

Effective date: 20181204

AS Assignment

Owner name: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT, ILLINOIS

Free format text: SECURITY INTEREST;ASSIGNOR:COVIS PHARMA B.V.;REEL/FRAME:047834/0926

Effective date: 20181204

Owner name: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL A

Free format text: SECURITY INTEREST;ASSIGNOR:COVIS PHARMA B.V.;REEL/FRAME:047834/0926

Effective date: 20181204

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: AMENDMENT AFTER NOTICE OF APPEAL

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT, ILLINOIS

Free format text: SECURITY INTEREST;ASSIGNOR:COVIS PHARMA B.V.;REEL/FRAME:052095/0262

Effective date: 20200310

AS Assignment

Owner name: COVIS PHARMA B.V., SWITZERLAND

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT;REEL/FRAME:052142/0961

Effective date: 20200310

AS Assignment

Owner name: COVIS PHARMA B.V., SWITZERLAND

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CAPITAL ONE, NATIONAL ASSOCIATION;REEL/FRAME:059043/0239

Effective date: 20220104